Navigation Links
New York Law Firm Files Lawsuit Against Manufacturer of Zicam Nasal Spray and Drugstore Chain That Sold Product
Date:7/8/2009

Leading personal injury law firm files complaint, alleging permanent damage to Long Island man's sense of smell and taste

Mineola, N.Y.(Lexis Nexis) July 8, 2009 -- Marc Grossman, senior partner of leading national personal injury law firm of Sanders Viener Grossman, LLP, in Mineola, N.Y., today announced that his firm has filed a civil lawsuit against the manufacturer of the popular Zicam nasal spray and the national drugstore chain that sold the product to a New York man who is alleging permanent injuries from his use of Zicam.

The lawsuit, Coleman et al v. Matrixx Intiatives, Inc. et al (Case Number 2:09-cv-2838), was filed last Thursday in the U.S. District Court, Eastern District of New York. The complaint alleges that Donald Coleman, a Bohemia, N.Y. resident, purchased a bottle of "Zicam Cold Remedy Nasal Spray" at a CVS Pharmacy store. After using the spray for about a week, and although the label stated it was "safe and effective" and a "patented homeopathic" remedy for cold symptoms, Mr. Coleman claims that he permanently lost his senses of smell and taste.

On June 16, 2009, the U.S. Food and Drug Administration (FDA) issued a public health advisory warning consumers to stop using and discard Zicam Cold Remedy Nasal Spray products, because the agency received greater than 130 reports of Anosmia, the medical term for a loss of smell and taste. As an over-the-counter product, neither the Zicam Cold Remedy Nasal Spray nor its labeling has ever been approved by the FDA.

"This is a clear example of an unregulated and unsafe product masquerading as a product that promotes good health" said Mr. Grossman, who is representing Mr. Coleman and numerous other individuals who used Zicam. "Rather than a minor cold, Mr. Coleman now has a permanent injury that deprives him of enjoying foods and aromas that he loved. The suspected culprit is zinc gluconate, listed as the active ingredient in Zicam products."

According to Mr. Grossman, zinc has long been purported as a cure for the common cold, but clinical studies dating back to 1937 have demonstrated that the application of substances containing zinc ions to the lining of the sinuses is toxic to cells that act as "smell receptors." As these cells die, so does not only one's sense of smell, but also taste.

Sanders Viener Grossman, LLP is one of the largest national law firms specializing in protecting the rights of innocent victims who have suffered personal injury as the result of the negligence of others. The firm is well-known for its successful litigation in a wide range of personal injury and products liability cases involving allegedly defective drugs, including headline-grabbing matters against Pfizer, Merck and other leading pharmaceutical companies.

For more information about Sanders Viener Grossman, LLP, please visit www.thesandersfirm.com or call 1.800.FAIRPLAY.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2611684.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. CareFusion Files Amended Form 10 Registration Statement With SEC
2. Novo Nordisk Insulin Analogs Have Proven Safety Profiles
3. Discus Dental Files Suit to Protect BriteSmile(R) Trademark
4. WuXi PharmaTech Files 2008 Annual Report on Form 20-F
5. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
6. Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders
7. Watson Files FDA Application for Generic Mucinex(R) D
8. Profiles International Releases New Report on Top 5 Management Failures and Remedies for Success
9. Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
10. CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS)
11. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held last ... Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred ... Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served APDA ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Stuart ... tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal today, Dr. ... with unmatched results. , Developed by Cynosure, the PicoSure has been approved by the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is ... one drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect ... package includes a 3D slideshow environment with 1 to 5 focus points per scene, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Health and wellness ... relevant to individuals in the event they are experiencing an illness. Migraines are a ... Americans that are afflicted with migraines would not wish the pain on their worst ...
(Date:2/5/2016)... ... 2016 , ... On June 9-10, Las Vegas will host ... (CME) event presented by the Association for Comprehensive Care in Rare Diseases (ACCORD). ... mission is to provide education, tools, and resources to primary care clinicians that ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Bernstein Liebhard LLP today announced that a securities class ... for the District of Arizona on ... or entities who purchased common shares of Insys Therapeutics Inc. ... 3, 2015 through January 25, 2016 (the "Class Period").  The ... of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... , Feb. 4, 2016 Global Immunology ... market to drive long-term market growth Summary ... set of chronic disorders that affect 5–7% of ... terms of their symptoms and key patient demographics, ... of immune pathways and an inappropriate immune response. ...
(Date:2/4/2016)... SPRING, Md. , Feb. 4, 2016 In ... Califf , the FDA,s Deputy Commissioner for Medical Products and ... action plan to reassess the agency,s approach to opioid medications. ... epidemic, while still providing patients in pain access to effective ... The FDA will: , Re-examine the risk-benefit paradigm ...
Breaking Medicine Technology: